Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT

Main Article Content

Christos C Zouboulis
Amit Garg
Christopher J. Sayed
Gregor Jemec
Georgios Kokolakis
John R. Ingram
Akimichi Morita
Pratiksha Dokhe
Ingrid Pansar
Robert Rolleri
Christina Crater
Asim Datye
Alexa B. Kimball

Keywords

Bimekizumab, hidradenitis suppurativa, interleukin-17A, interleukin-17F

Abstract

Introduction: Interleukin (IL)-17F and IL-17A play a role in the immunopathogenesis of hidradenitis suppurativa (HS).1–3 Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody that selectively inhibits IL-17F in addition to IL-17A leading to clinically meaningful improvements in patients (pts) with HS.4,5 Here, BKZ efficacy and safety data (OC) are presented over 2 years (96 weeks [wks]) for the pooled BE HEARD I&II (BHI&II) trials and BE HEARD EXT (BHEXT).5,6


Procedure/Study: In BHI&II, pts with moderate to severe HS were randomized 2:2:2:1 (16wk-initial/32wk-maintenance) to BKZ 320mg every 2 wks (Q2W)/Q2W, BKZQ2W/Q4W, BKZQ4W/Q4W or placebo/BKZQ2W.5 Wk48 completers could enroll in BHEXT and receive open-label BKZQ2W or BKZQ4W based on ≥90% HS Clinical Response (HiSCR90; averaged from Wks36/40/44). We report HiSCR50/75/90/100 rates, percentage change from baseline (%CfB, mean±SD) in International HS Severity Score System (IHS4) and draining tunnel (DT) count, and Dermatology Life Quality Index (DLQI) 0/1 achievement at Wks48/96 for patients randomized to BKZ in BHI&II and entered BHEXT (BKZ Total, observed case). Safety outcomes reported for pts who received ≥1 BKZ dose across BHI&II/BHEXT.


Results: 556 pts randomized at baseline to BKZ in BHI&II completed Wk48 and entered BHEXT; 446 pts completed Wk96. At Wk48, HiSCR50/75/90/100 was achieved by 79.9/64.0/42.3/30.2% of pts; responses improved to Wk96: 85.4/77.1/57.6/44.2%. Baseline IHS4 was 35.6±31.5; %CfB at Wk48/96 was
–70.3±39.6/−79.8±28.1%. Baseline DTs were 3.8±4.3; the %CfB at Wk48/96 was −57.5±72.9%/−73.7±45.7%. Baseline DLQI was 11.0±6.8; 27.4% (151/551) of pts achieved DLQI 0/1 at Wk48 and 33.9% (149/439) at Wk96. Over 2 years, 917/995 (248.9/100 pt years [PY]) pts experienced a treatment-emergent adverse event (TEAE). Serious TEAEs were reported in 122 (7.2/100 PY) pts; 109 (6.3/100 PY) pts discontinued due to a TEAE. Serious infections occurred in 33 (1.9/100 PY) pts. Safety data were comparable with BHI&II.5


Conclusion: In pts treated with BKZ, clinically meaningful improvements in efficacy outcomes observed at 1 year, including the HiSCR 75/90/100, IHS4, and DT count endpoints, were maintained to 2 years; improvements in quality of life were maintained. No new safety signals were observed; the safety profile over 2 years was consistent with BHI&II and BKZ studies in other indications.5,7–9

References

Zouboulis CC et al. Exp Dermatol 2020;29:1154–70;

Skelton A et al. J Invest Dermatol 2023;143:S87;

Kimball AB et al. Exp Dermatol 2022;31:1522–32;

Zouboulis VA et al. Pharmaceutics 2021;14:44;

Adams R et al. Front Immunol 2020;11:1894;

Kimball AB et al. Lancet 2024;403:2504–19 (NCT04242446, NCT04242498);

BE HEARD EXT: https://clinicaltrials.gov/study/NCT04901195;

Glatt S et al. JAMA Dermatol 2021;157:1279–88;

Kimball AB et al. N Engl J Med 2016;375:422–34;

Reich K et al. N Engl J Med 2021;385:142–52;

Merola JF et al. Lancet 2023;401:38–48;

van der Heijde D. Ann Rheum Dis 2023;82:515–26;

Heijde D et al. Ann Rheum Dis 2023;82:515–2.

Most read articles by the same author(s)

1 2 3 > >>